Integrin Beta Market
Global Integrin Beta Market Size, Share and Trends Analysis Report, By Type (IGBT1, IGBT2, IGBT3, IGBT4, IGBT5, IGBT6, IGBT7, and IGBT8), By Application (Genetic Disorder, CVD, Cancer, and Others), Forecast (2022-2028) Update Available - Forecast 2024-2030
The global integrin beta market is anticipated to grow at considerable CAGR of around 6.5% during the forecast year. Integrins are proteins that function mechanically and attach to the cell cytoskeleton to the extracellular matrix (ECM), and biochemically through sensing if adhesion has occurred. The factor driving the growth of the market is several clinical trials going of various types of integrin beta for the treatment of various diseases such as, cancer, hepatic fibrosis, glioblastoma and others. For instance, in June 2020, Seattle Genetics, Inc., announced dosing of the first patient in a phase 1 clinical trial evaluating investigational agent SEA-TGT, also known as SGN-TGT, an anti-TIGIT antibody for patients with solid tumors and lymphomas. Moreover, it has also announced, first patient in a phase 1 clinical trial evaluating investigational agent SGN-B6A, an antibody-drug conjugate (ADC) targeting integrin beta-6, that is over expressed in numerous solid tumors.
Impact of COVID-19 on Global Integrin Beta Market
COVID-19 not only brings tremendous pressure to the medical system but it has also brought new challenges for the global economy. It has impacted integrin beta market due to impact on various diagnosis, treatment, and research and development all were focused on working for COVID-19 the integrin beta demand was less the revenue of the integrin beta market also laid down. The integrin beta market in the COVID-19 pandemic impacted due to its application in several medicinal departments including dermatology, oncology, and genetic disorder for the treatment of various diseases and also in research and development of various drugs.
Segmental Outlook
The global integrin beta market is segmented based on type and application. Based on type, the market is sub-segmented intoIGBT1, IGBT2, IGBT3, IGBT4, IGBT5, IGBT6, IGBT7, and IGBT8. Based on application, the market is sub-segmented into Genetic Disorder, CVD, Cancer, and others. Among the type segment the IGBT 1 is dominating in the market owing to increase in cancer cases. IGBT1 is majorly used to mediate the interactions between cells-cells and cells-ECM also this is used in oncogenic transformation of normal cells and their growth into a primary tumour node.
Global Integrin beta Market by Application, 2021(%)
The Genetic Disorder Segment is dominating in the Global Integrin Beta Market
The use of integrin beta in the genetic disorder segment is expected to hold a major share in the global integrin beta market due to the increasing cases of genetic disorders patients across the globe. For instance, According to a report published by National Org. for Rare Disease (NORD), the genetic disorder is a rare disease that can affect any age group i.e., from infant to 80 years. The most common age group affected by genetic disorders is between 40 years and 60 years. There are around 9.63 cases per million people estimated to get affected by genetic disorders. Around 3 in 1 million children are affected by juvenile genetic disorders. Genetic disorders occur when mutations (harmful mutations in a gene, also known as pathogenic mutations) affect genes. To cure genetic disorder, integrin beta is used in various. These increasing cases of genetic disorders are increasing the demand for treatment propelling the growth of the global integrin beta market.
Regional Outlooks
The global Integrin beta market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). The North American region is expected to hold the major share in the global integrin beta market due to the presence of several key players and several clinical trials done by players in the region.
Global Integrin beta Market Growth by Region, 2022-2028
The Asia Pacific Region is the fastest growing in the Global Integrin beta Market
Asia Pacific region is expected to be dominating in the global integrin beta market owing to developing healthcare infrastructure and various government initiatives, rules, and regulations are made on the drug development in the region. Moreover, the rising cancer cases, increasing genetic disorders, various health benefits in intake of integrin beta, and, the population becoming health conscious are such factors that are boosting market growth. For instance, as per the report published by Global Data in November 2021, the Asia-Pacific region has seen a 184% increase in the number of genetic disorders. From 2010 and 2020, there was a 184% increase in the number of trials taking place in the Asia Pacific. In 2020, the largest proportion of trials took place in Japan with 28.4% of all trials. Moreover, Australia and China were the largest percentages of holding trials taking place in the region with 25% and 21.6%, respectively. These are the factors due to that the market is expected to be the fastest growing.
Market Players Outlook
The major companies serving the global Integrin beta market include AstraZeneca, Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Novartis International AG, Pfizer Inc., and many others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches. For instance, in June 2021, ProMetic Biotherapeutics Inc. announced the approval of Ryplazim (plasminogen, human-tvmh) from the US FDA. It is used to treat type 1 plasminogen deficiency, a disorder that can damage normal tissues and organ function and can lead to blindness.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global integrin beta market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on The Global Integrin BetaMarket
- Recovery Scenario of Global Integrin BetaMarket
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. AstraZeneca
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Eli Lilly and co.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. F. Hoffmann-La Roche Ltd.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Novartis International AG
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Pfizer Inc.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Integrin Beta Market by Type
4.1.1. IGBT 1
4.1.2. IGBT 2
4.1.3. IGBT 3
4.1.4. IGBT 4
4.1.5. IGBT 5
4.1.6. IGBT 6
4.1.7. IGBT 7
4.1.8. IGBT 8
4.2. Global Integrin Beta Market by Application
4.2.1. Genetic Disorder
4.2.2. CVD
4.2.3. Cancer
4.2.4. Others
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Abbott Laboratories
6.2. Avipero
6.3. Biogen Inc.
6.4. Bristol Myers Squibb (BMS)
6.5. Clanotech AB
6.6. Corbus Pharmaceuticals, Inc.
6.7. GlaxoSmithKline plc
6.8. Idera Pharmaceuticals, Inc.
6.9. Merck Group
6.10. Morphic Therapeutic
6.11. Neovacs
6.12. Octapharma AG
6.13. SciFluor Life Sciences, LLC
6.14. Springer Nature Ltd.
6.15. Takeda Pharmaceuticals Co. Ltd.
6.16. Thermo Fisher Scientific Inc.
6.17. Valeant Pharmaceuticals International Inc.
6.18. Viatris Inc.
6.19. Virtual Drug Development Inc.
6.20. Vascular Pharmaceuticals, Inc
1. GLOBAL INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL IGBT 1 INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL IGBT 2 INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL IGBT 3 INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL IGBT 4 INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL IGBT 5 INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL IGBT 6INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL IGBT 7 INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL IGBT 8 INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY APLLICATION,2021-2028 ($ MILLION)
11. GLOBAL INTEGRIN BETA IN GENETIC DISORDER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL INTEGRIN BETA IN CVD MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL INTEGRIN BETA IN CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. GLOBAL OTHERS INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
15. GLOBAL INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
16. NORTH AMERICAN INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. NORTH AMERICAN INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
18. NORTH AMERICAN INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
19. EUROPEAN INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. EUROPEAN INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
21. EUROPEAN INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
22. ASIA-PACIFIC INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
23. ASIA-PACIFIC INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY TYPE,2021-2028 ($ MILLION)
24. ASIA-PACIFIC INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY APPLICATION,2021-2028 ($ MILLION)
25. REST OF THE WORLD INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
26. REST OF THE WORLD INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
27. REST OF THE WORLD INTEGRIN BETA MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL INTEGRIN BETA MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL INTEGRIN BETA MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL INTEGRIN BETA MARKET, 2021-2028 (%)
4. GLOBAL INTEGRIN BETA MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL IGBT 1 INTEGRIN BETA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL IGBT 2 INTEGRIN BETA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL IGBT 3 INTEGRIN BETA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL IGBT 4 INTEGRIN BETA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBALIGBT 5 INTEGRIN BETA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL IGBT 6 INTEGRIN BETA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL IGBT 7 INTEGRIN BETA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL IGBT 8 INTEGRIN BETA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL INTEGRIN BETA MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
14. GLOBALINTEGRIN BETAIN GENETIC DISORDER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. GLOBAL INTEGRIN BETA IN CVD MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. GLOBAL INTEGRIN BETA IN CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
17. GLOBAL INTEGRIN BETA IN OTHERMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
18. GLOBAL INTEGRIN BETA MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
19. US INTEGRIN BETA MARKET SIZE, 2021-2028 ($ MILLION)
20. CANADA INTEGRIN BETA MARKET SIZE, 2021-2028 ($ MILLION)
21. UK INTEGRIN BETA MARKET SIZE, 2021-2028 ($ MILLION)
22. FRANCE INTEGRIN BETA MARKET SIZE, 2021-2028 ($ MILLION)
23. GERMANY INTEGRIN BETA MARKET SIZE, 2021-2028 ($ MILLION)
24. ITALY INTEGRIN BETA MARKET SIZE, 2021-2028 ($ MILLION)
25. SPAIN INTEGRIN BETA MARKET SIZE, 2021-2028 ($ MILLION)
26. REST OF EUROPE INTEGRIN BETA MARKET SIZE, 2021-2028 ($ MILLION)
27. INDIA INTEGRIN BETA MARKET SIZE, 2021-2028 ($ MILLION)
28. CHINA INTEGRIN BETA MARKET SIZE, 2021-2028 ($ MILLION)
29. JAPAN INTEGRIN BETA MARKET SIZE, 2021-2028 ($ MILLION)
30. SOUTH KOREA INTEGRIN BETA MARKET SIZE, 2021-2028 ($ MILLION)
31. REST OF ASIA-PACIFIC INTEGRIN BETA MARKET SIZE, 2021-2028 ($ MILLION)
32. REST OF THE WORLD INTEGRIN BETA MARKET SIZE, 2021-2028 ($ MILLION)
